Blog

Latest News

Elon Musk Continues To Defend Ketamine

Read More
Silo Pharma

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent…

Cybin

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. Doug Drysdale, Chief Executive Officer of Cybin will participate in a…

Cybin

Cybin Inc. – Announces Oversubscribed Private Placement of U.S. $150 Million

TORONTO – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (‘Cybin’ or the ‘Company’), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce a proposed private placement of 348,837,210 common shares in the capital of the Company at a price of U.S.$0.43 per Common Share representing…